Compare Quest Diagnostics Inc (DGX) vs JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs JPMorgan Nasdaq Equity Premium Income ETF — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while JPMorgan Nasdaq Equity Premium Income ETF trades at $61.09 (market cap $44.49B). The key difference: JPMorgan Nasdaq Equity Premium Income ETF is the larger of the two by market cap, and Quest Diagnostics Inc pays a 1.49% dividend while JPMorgan Nasdaq Equity Premium Income ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and JPMorgan Nasdaq Equity Premium Income ETF for 66 Days on average.
| DGX | JEPQ | |
|---|---|---|
Market Cap | $25.48B | $44.49B |
Volume | 941,866 | 5,681,789 |
Sector | Health | Income / Options Overlay |
52-Week High | $247.45 | $61.46 |
52-Week Low | $173.49 | $53.77 |
Typical Hold Time | 56 Days | 66 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
JEPQ trades at $60.93, down 0.55% on the day, with a bullish technical signal from moving averages while oscillators remain neutral. The ETF's covered-call strategy generates substantial monthly income, with recent dividends ranging from $0.57 to $0.70 per share. Recent news highlights JEPQ's 11% estimated annual yield and its positioning in AI-driven tech stocks, though the strategy limits upside potential during strong market rallies.
JEPQ offers high income generation through its Nasdaq-focused covered-call approach, making it attractive for retirees seeking monthly cash flow. However, the strategy caps appreciation potential and faces volatility sensitivity, requiring proper portfolio sizing. Key risks include market volatility dependence and competitive pressure from similar income ETFs with different tax treatments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About JPMorgan Nasdaq Equity Premium Income ETF
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →
